The Mito Stack: SS-31, MOTS-c, and NAD+ — A Mitochondrial Research Guide

Why mitochondrial function declines with age

Mitochondria produce approximately 90% of the body's energy as ATP through the electron transport chain (ETC) embedded in the inner mitochondrial membrane. Three interdependent failure points drive age-related mitochondrial decline. First, cardiolipin — the phospholipid that anchors the ETC machinery in place — degrades with age and oxidative stress, loosening the respiratory complexes and reducing energy efficiency while increasing reactive oxygen species (ROS) production. Second, AMPK signaling — the master metabolic switch that drives mitochondrial biogenesis — becomes progressively blunted, reducing the body's ability to build new mitochondrial capacity. Third, NAD+ levels decline approximately 50% between ages 20 and 50, depleting the coenzyme that powers the ETC itself.

The Mito Stack addresses all three failure points sequentially: SS-31 repairs the membrane (failure point one), MOTS-c restores AMPK signaling (failure point two), and NAD+ replenishes the coenzyme pool (failure point three).

SS-31: repairing the inner membrane

SS-31 (elamipretide, also known as Forzinity) is a synthetic aromatic-cationic tetrapeptide engineered to concentrate at the inner mitochondrial membrane at levels approximately 1,000–5,000 times higher than surrounding cellular tissue. Its mechanism is precise: SS-31 binds cardiolipin, stabilizing it and tightening the respiratory supercomplex architecture that holds ETC components I, III, and IV in place. When cardiolipin is stabilized, electron flow through the ETC becomes more efficient, ATP output increases, and ROS production decreases simultaneously.

In aged mice, a single SS-31 injection restored in vivo mitochondrial energetics to young-mouse levels within one hour — a finding that established SS-31 as one of the most acutely effective mitochondrial interventions in preclinical research. In September 2025, SS-31 (as elamipretide/Forzinity) received FDA accelerated approval for Barth syndrome, a rare genetic disorder defined by defective cardiolipin remodeling. This makes SS-31 the first mitochondria-targeted therapeutic to receive FDA approval.

Research protocol: 4.67mg reconstituted in 1ml bacteriostatic water, administered daily for 21 days subcutaneously. See the SS-31 research profile for full specifications and interactive dose calculator.

MOTS-c: the metabolic adaptation signal

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid peptide uniquely encoded within the mitochondrial genome — one of the few known peptides not originating from nuclear DNA. This gives it a direct and fundamental relationship with mitochondrial metabolic state. Under metabolic stress, MOTS-c translocates from mitochondria to the cell nucleus, where it binds stress-response transcription factors NRF2 and ATF1 to reprogram cellular metabolism.

Its primary signaling mechanism activates AMPK — the master metabolic switch triggered by intense exercise — driving glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. This is why MOTS-c is sometimes described as mimicking the cellular effects of exercise. A 2021 Nature Communications study showed MOTS-c levels in skeletal muscle increase 11.9-fold with exercise, and a 2025 Nature study demonstrated MOTS-c prevents pancreatic islet cell senescence, reducing diabetes progression in animal models.

MOTS-c levels decline approximately 21% between ages 18–30 and ages 70–81. Blood levels are measurably lower in individuals with type 2 diabetes, gestational diabetes, and obesity. Research protocol: 5–10mg reconstituted in 1ml bacteriostatic water, one injection every 5 days for 20 days (4 injections per cycle), 3 cycles per year. See the MOTS-c research profile.

NAD+: the coenzyme foundation

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of the body. While technically a coenzyme rather than a peptide, injectable NAD+ is included in mitochondrial protocols because it participates in the same energy production pathways as MOTS-c and SS-31. NAD+ is required for the electron transport chain, over 500 enzymatic reactions, sirtuin activation (SIRT1–SIRT7), and PARP-mediated DNA repair. Without sufficient NAD+, mitochondria cannot efficiently convert nutrients into ATP regardless of how well the membrane is structured (SS-31) or how strongly AMPK is signaled (MOTS-c).

Injectable NAD+ bypasses the conversion steps required for oral precursors like NMN and nicotinamide riboside, delivering direct bioavailability. Research protocol: 50–150mg intramuscular, 10 units daily or 20–30 units twice weekly throughout the Mito Stack cycle. See the database for the full NAD+ entry.

The protocol sequence

The sequence of the Mito Stack matters because SS-31 creates the optimal structural foundation for MOTS-c to work on. Beginning with MOTS-c on a membrane compromised by cardiolipin degradation is like trying to improve engine performance without first fixing structural damage. The recommended research sequence: Phase 1 (weeks 1–3): SS-31 daily to repair membrane integrity. Phase 2 (weeks 4–8): add MOTS-c every 5 days to drive biogenesis on the now-repaired foundation. NAD+ continues throughout both phases. This 12-week protocol is repeated 2–3 times per year.

The complete Mito Stack protocol is available in the Peptide Hub database. Individual profiles with interactive dose calculators are available for SS-31, MOTS-c, and NAD+.

Research references

• Szeto HH (2011). Mitochondria-targeted peptide antioxidants — PubMed
• Lee C, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis — PubMed
• Reynolds JC, et al. (2021). MOTS-c is an exercise-induced mitochondrial encoded regulator — PubMed

Research sourcing: For research-grade SS-31, MOTS-c, and NAD+ with third-party COA documentation, Peptide Hub recommends Amino Club (partner code: PEPTIDEHUB). Affiliate link — we earn a commission at no cost to you.